3.1 Neurodevelopmental and Schizophrenia Spectrum Disorders
Key Takeaways
- Schizophrenia diagnosis requires at least 2 of 5 core symptoms (delusions, hallucinations, disorganized speech, disorganized behavior, negative symptoms) for 1 month, with total illness duration of at least 6 months.
- Schizophreniform disorder shares the same symptomatic presentation as schizophrenia but is distinguished by a duration of 1 to 6 months.
- Schizoaffective disorder involves an uninterrupted period of illness with a major mood episode concurrent with Criterion A of schizophrenia, plus delusions or hallucinations for 2 or more weeks in the absence of a major mood episode.
- ADHD diagnostic criteria require symptom onset prior to age 12, manifesting in at least two settings, with 6+ symptoms for children and 5+ for adults (age 17 and older).
- Second-generation antipsychotics combine 5-HT2A serotonin antagonism with D2 dopamine receptor blockade, reducing extrapyramidal symptoms (EPS) below 5% compared to > 20% with high-potency first-generation antipsychotics.
Neurodevelopmental and Schizophrenia Spectrum Disorders
Exam Tip: The timeline is the most critical factor in differentiating brief psychotic disorder, schizophreniform disorder, and schizophrenia on the exam. Always look for the duration of symptoms.
1. Schizophrenia Spectrum Disorders
Schizophrenia is a chronic, severe mental disorder characterized by psychosis, apathy, and social withdrawal. The exact etiology is unknown but involves a combination of genetic vulnerabilities, environmental stressors, and neurochemical abnormalities (particularly the dopamine hypothesis).
DSM-5-TR Diagnostic Criteria for Schizophrenia
Criterion A: Two (or more) of the following, each present for a significant portion of time during a 1-month period. At least one of these must be (1), (2), or (3):
- Delusions (fixed, false beliefs)
- Hallucinations (perceptual experiences without external stimuli, usually auditory)
- Disorganized speech (e.g., frequent derailment or incoherence)
- Grossly disorganized or catatonic behavior
- Negative symptoms (i.e., diminished emotional expression or avolition)
Criterion B: Social/occupational dysfunction in one or more major areas (work, interpersonal relations, self-care) below the level achieved prior to onset. Criterion C: Continuous signs of the disturbance persist for at least 6 months, including the 1-month active phase; the remainder may include prodromal or residual symptoms or attenuated positive symptoms. Criterion D: Schizoaffective disorder and depressive/bipolar disorder with psychotic features have been ruled out. Criterion E: The disturbance is not attributable to substance effects or another medical condition.
Differential Diagnosis of Psychotic Disorders
| Disorder | Key Features & Duration | Mood Symptoms |
|---|---|---|
| Brief Psychotic Disorder | 1 day to < 1 month. Full return to premorbid functioning. | Not a core feature. |
| Schizophreniform Disorder | 1 month to < 6 months. Similar to Schizophrenia but shorter. | Not a core feature. |
| Schizophrenia | ≥ 6 months. Significant functional decline. | Brief compared to active phase. |
| Schizoaffective Disorder | Major mood episode concurrent with Criterion A. Delusions/hallucinations for ≥ 2 weeks without mood symptoms. | Prominent mood episodes. |
| Delusional Disorder | ≥ 1 month of delusions. No other psychotic symptoms. Functioning is generally preserved. | Not prominent. |
Differentiating Schizophrenia from Psychotic Mood Disorders
A common exam trap involves distinguishing schizophrenia from bipolar disorder with psychotic features or major depressive disorder with psychotic features. The key discriminator is the temporal relationship between psychosis and mood symptoms. In psychotic mood disorders, delusions or hallucinations occur only during the mood episode. In schizoaffective disorder, the patient experiences delusions or hallucinations for at least 2 weeks in the absence of a major mood episode. Always map symptoms on a timeline before assigning a diagnosis.
Positive vs. Negative Symptoms
- Positive Symptoms: Hallucinations, delusions, disorganized speech, disorganized behavior. Driven by hyperactive dopamine transmission in the mesolimbic pathway.
- Negative Symptoms: Affective flattening, alogia (poverty of speech), avolition (lack of drive), anhedonia, asociality. Associated with dopamine deficit in the mesocortical pathway.
- Cognitive Symptoms: Deficits in working memory, executive function, and attention. These are the strongest predictor of long-term functional outcome and respond poorly to current antipsychotics.
Pharmacological Treatment
- First-Generation Antipsychotics (FGAs): (e.g., Haloperidol, Chlorpromazine, Fluphenazine) Strong D2 receptor antagonists. Effective for positive symptoms but carry high risk of Extrapyramidal Symptoms (EPS) (dystonia, akathisia, parkinsonism, tardive dyskinesia). Haloperidol typical adult dose 5-20 mg/day; potent EPS risk, especially in young males for acute dystonia.
- Second-Generation Antipsychotics (SGAs): (e.g., Risperidone, Olanzapine, Clozapine, Aripiprazole, Quetiapine) Serotonin-dopamine antagonists (5-HT2A and D2). Effective for positive and negative symptoms. Lower EPS risk but higher risk of Metabolic Syndrome (weight gain, dyslipidemia, hyperglycemia). Baseline and quarterly monitoring of BMI, waist circumference, fasting glucose, and lipid panel is required.
- Clozapine (Clozaril): Reserved for treatment-resistant schizophrenia (failure of 2+ adequate antipsychotic trials at therapeutic doses for 6+ weeks). High risk of agranulocytosis; requires strict ANC monitoring through the REMS program: weekly for 6 months, biweekly for the next 6 months, then monthly. ANC below 1500 requires interruption. Also carries significant risk of myocarditis, seizures, and severe constipation.
2. Neurodevelopmental Disorders
Attention-Deficit/Hyperactivity Disorder (ADHD)
ADHD is a neurodevelopmental disorder defined by impairing levels of inattention, disorganization, and/or hyperactivity-impulsivity.
Diagnostic Criteria (DSM-5-TR):
- Symptoms: ≥ 6 symptoms of inattention AND/OR ≥ 6 symptoms of hyperactivity/impulsivity for children. For older adolescents and adults (17+), only 5 symptoms are required.
- Duration: Present for at least 6 months.
- Onset: Several symptoms must have been present prior to age 12.
- Pervasiveness: Symptoms must be present in two or more settings (e.g., home and school/work).
- Exclusion: Not better explained by another mental disorder (e.g., anxiety, mood disorder, schizophrenia).
Presentation Specifiers: Combined presentation, Predominantly inattentive presentation, Predominantly hyperactive-impulsive presentation. Specifier changes based on the current symptom pattern.
Treatment Pathway:
- First-line (School-age children/adults): Stimulants (Methylphenidate, Amphetamine derivatives). Mechanism: Block reuptake of dopamine and norepinephrine. FDA boxed warning regarding potential for cardiovascular events and abuse/dependence; however, the risk of new-onset psychosis at therapeutic doses is low.
- Second-line or specific patient profiles (e.g., substance abuse risk): Non-stimulants like Atomoxetine (SNRI, requires 4-6 weeks for effect), Guanfacine XR, Clonidine XR (Alpha-2 agonists, useful for hyperactivity/impulsivity and comorbid tics).
Autism Spectrum Disorder (ASD)
ASD involves persistent deficits in social communication and social interaction across multiple contexts, accompanied by restricted, repetitive patterns of behavior, interests, or activities.
DSM-5-TR Criteria (two domains):
- Domain A (Social communication): Deficits in social-emotional reciprocity; deficits in nonverbal communicative behaviors (eye contact, body language); deficits in developing and maintaining relationships.
- Domain B (Restricted/repetitive patterns): Stereotyped or repetitive motor movements, speech (echolalia), or use of objects; insistence on sameness/ritualized patterns; restricted fixated interests of abnormal intensity; hyper- or hyporeactivity to sensory input.
Severity Specifiers (Level 1, 2, 3): Based on the amount of support required. Level 1 ("requiring support"), Level 2 ("requiring substantial support"), Level 3 ("requiring very substantial support"). Specifier also notes with or without intellectual impairment, with or without language impairment.
Treatment: Primarily behavioral interventions (e.g., Applied Behavior Analysis). FDA-approved medications for irritability/aggression in ASD include Risperidone and Aripiprazole. SSRIs may help comorbid anxiety but can activate agitation in some patients.
Clinical Vignette: A 19-year-old college student is brought in by his roommate. The roommate states that for the past 5 weeks, the patient has been barricading the door, claiming the government is tracking him, and talking to people who aren't there. The patient's functioning has declined, and he has stopped attending classes. Diagnosis: Schizophreniform disorder (duration is 5 weeks; >1 month but <6 months).
Worked Example — Differentiating ASD and ADHD: A 7-year-old boy has trouble making friends, avoids eye contact, lines up toy cars, and becomes distressed when routines change. He focuses intently on dinosaurs. Although he also has attention problems in class, the restricted interests, sensory sensitivities, and social-reciprocity deficits point to ASD rather than ADHD. Both can be comorbid; the PMHNP must document which criteria are met for each.
A 22-year-old male presents with auditory hallucinations, paranoia, and disorganized speech that began 3 months ago. He has no history of mood episodes. What is the most appropriate diagnosis?
Which of the following neural pathways is primarily associated with the negative symptoms of schizophrenia?
A mother brings her 10-year-old son for evaluation. He struggles to pay attention in class, frequently loses his homework, and fidgets constantly. The mother notes these behaviors have been present since age 6 but only occur at school; at home, he is calm and focused on his video games. Does he meet DSM-5-TR criteria for ADHD?